Xenon Pharmaceuticals (NASDAQ:XENE) just reported results for the first quarter of 2024.
- Xenon Pharmaceuticals reported earnings per share of -62 cents. This was above the analyst estimate for EPS of -66 cents.
- The company did not report any revenue for the quarter.